Tomato/tomahto? Teva tbo-filgrastim OK'd, but FDA says 'not biosimilar to Neupogen'
This article was originally published in Scrip
Executive Summary
The US FDA on 29 August granted Teva and its subsidiary Sicor Biotech the go-ahead to market tbo-filgrastim, a short-acting recombinant form of granulocyte colony-stimulating factor (G-CSF), in the US as a therapy to reduce the duration of severe neutropenia in patients with non-myeloid malignancies receiving chemotherapy that affects the bone marrow.